vendredi 15 février 2013

Press Review (February 16, 2013) – Revue de presse (16 février 2013)

Study Points to Shorter Treatments for Prostate Cancer
Men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a more standard 36 months, a new study has found.
By Andrew Pollack. In The New York Times

Report Faults Priorities in Studying Breast Cancer
Too little of the money the federal government spends on breast cancer research goes toward finding environmental causes of the disease and ways to prevent it, according to a new report from a group of scientists, government officials and patient advocates established by Congress to examine the research.
By Denise Grady. In The New York Times

Protein Central to Cancer Stem Cell Formation Provides New Potential Target
Researchers have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development.
In Science Daily

Childhood Cancer Survivors Who Received Chest Irradiation at Risk for Pulmonary Hypertension in Middle Age
St. Jude Children's Research Hospital investigators found evidence that chest irradiation may leave some adult survivors of childhood cancer in danger of developing pulmonary hypertension in middle age.
In Science Daily

Lung cancer set to overtake breast cancer as the main cause of cancer deaths among European women
Lung cancer is likely to overtake breast cancer as the main cause of cancer death among European women by the middle of this decade, according to new research published in the cancer journal Annals of Oncology [1] today (Wednesday). In the UK and Poland it has already overtaken breast cancer as the main cause of cancer deaths in women.
In EurekAlert (press release)

Emerging Cancer Drugs May Drive Bone Tumors
Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone, according to researchers at Washington University School of Medicine in St. Louis.
In Science Daily

Researchers Discover Biological Diversity in Triple-Negative Breast Cancer
Triple-negative breast cancers are more biologically diverse than previously believed and classification should be expanded to reflect this heterogeneity, according to University of North Carolina researchers.
In Science Daily

Copper depletion therapy keeps high-risk triple-negative breast cancer at bay
An anti-copper drug compound that disables the ability of bone marrow cells from setting up a "home" in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in one of the most difficult-to-treat forms of cancer -- high-risk triple-negative breast cancer.
In EurekAlert (press release)

Eradicating Bacteria Linked to Gastric Cancer
In an analysis of the results of interventions to eradicate the bacterium Helicobacter pylori (a risk factor for gastric cancer) in seven diverse community populations in Latin America, researchers found that geographic site, demographic factors, adherence to initial therapy and infection recurrence may be as important as the choice of antibiotic regimen in H pylori eradication interventions, according to a study appearing in the February 13 issue of JAMA.
In Science Daily

Le cancer du poumon explose chez la femme
En 2015, le cancer du poumon tuera plus de femmes en Europe que le cancer du sein. Ce sombre pronostic est issu de projections publiées mercredi dans les Annals of Oncology.
Par Delphine Chayet. Dans Le Figaro

Amiante : 18 000 à 25 000 décès par cancer de la plèvre d'ici 2030
Le pic des décès dus au mésothéliome (cancer de la plèvre) aurait en fait déjà été atteint, selon des travaux réalisés par l'InVS en partenariat avec le Centre d'épidémiologie sur les causes médicales de décès (CépiDc) de l'Inserm.
Dans Le Point

Cancer : un virus modifié suscite l'espoir d'un nouveau traitement
Un virus génétiquement modifié pour cibler les cellules tumorales vient de montrer qu’il augmentait significativement l’espérance de vie de patients en phase terminale du cancer du foie. Nommé Pexa-Vec et testé également pour d’autres cancers, il semblerait là encore plutôt efficace. Si tout se passe bien, il pourrait être proposé d’ici 5 ans.
Dans Futura Sciences

Des nanoparticules d'or radioactives contre le cancer
Les noyaux d’hélium produits par radioactivité alpha sont très efficaces pour tuer des cellules cancéreuses. Ils le sont malheureusement aussi pour tuer les cellules saines, ce qui a jusqu’ici posé problème pour lutter contre les cancers. On apprend comment contourner l'obstacle grâce aux nanotechnologies : en utilisant des nanoparticules d’or.
Dans Futura Sciences

Aucun commentaire:

Enregistrer un commentaire